Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yi-Tong Cheng-Zhang is a Traditional Chinese Medicine (TCM) oral liquid preparation developed by the Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine. It is specifically indicated for the treatment of elevated blood lead levels (lead poisoning) in pediatric patients. The formulation is designed to facilitate the excretion of lead from the body and reduce its absorption, likely through the action of herbal constituents such as *Poria cocos* and *Fructus Crataegi* (Hawthorn), which are traditionally used to promote detoxification and metabolic health. Additionally, such preparations often incorporate essential minerals like zinc and calcium to competitively inhibit lead uptake in the gastrointestinal tract. It is primarily utilized as a hospital-specific preparation (医院制剂) in China for mild to moderate lead exposure cases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yi-Tong Cheng-Zhang.